Market Overview

UPDATE: Bank of America Lowers Auxilium Pharmaceuticals PO to $25 Following 4Q12 Results

Related AUXL
Markets Mixed; Dollar Tree Profit Misses Estimates
Morning Market Movers

Bank of America published a report that reiterated Auxilium Pharmaceuticals (NASDAQ: AUXL) at Buy and trims price objective from $26 to $25.

Bank of America reported that, “We lowered our market growth assumptions for Testim based on recent Rx trends, and modestly increased our share estimates, which assume that AUXL's efforts to stabilize and grow share in 2013 are successful. These changes reduced our 2013E Testim sales to $252mn (from $257mn) and increased our 2014E sales to $302mn (from $293mn). We also lowered our Xiaflex sales estimates for 2013E to $71mn (from $85mn) and $104mn (from $119mn). Our new 2013E EPS is $0.15 (from $0.44) and our 2014E EPS is $0.98 (from $1.02).”

Auxilium Pharmaceuticals shares closed Tuesday at $17.06.

Posted-In: Bank of AmericaAnalyst Color Price Target Analyst Ratings


Related Articles (AUXL)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters